Clinical Trial Update: A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension [Phase 3]

View source ↗

Summary

Phase 3 trial comparing SDP-133 (Sun Pharma) daily with Lumigan in open-angle glaucoma or ocular hypertension was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Hypertension
• Open-angle Glaucoma

Drugs mentioned

• Lumigan (bimatoprost)
• SDP-133 (unspecified)

Snippet

Sponsor: Sun Pharmaceutical Industries Limited | Conditions: Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Status: WITHDRAWN